No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.
No article has been written about this topic yet.
Be the first one to add some text.
Loading AI-assisted edit mode...
Timeline
July 2019
Frequency Therapeutics raises a $62,000,000 series C round from Axil Capital, CoBro Ventures, Deerfield Management Company, Mizuho Securities, Perceptive Advisors, RTW Investments LLC and Taiwania Capital Management.
January 7, 2019
Frequency Therapeutics raises a $42,000,000 series B round from Taiwania Capital Management.
January 2019
Frequency Therapeutics raises a $42,000,000 series B round from Axil Capital, CoBro Ventures, DF Investments, Emigrant Capital, Korea Investment Partners, Polaris Founders Capital, Taiwania Capital Management and Yonjin Capital.
April 2017
Frequency Therapeutics raises a $32,000,000 series A round from Alexandria Real Estate Equities, CoBro Ventures, Emigrant Capital, Korea Investment Partners and Morningside Group.
Funding rounds
Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
42,000,000
January 2019
62,000,000
July 2019
32,000,000
April 2017
42,000,000
January 7, 2019
People
Name
Role
LinkedIn
Further reading
Title
Author
Link
Type
Date
Documentaries, videos and podcasts
Title
Date
Link
Companies
Company
CEO
Location
Products/Services
News
Title
Author
Date
Publisher
Description
April 13, 2021
BioSpace
Frequency Therapeutics Expands its Clinical Development Team, Adding Expertise in Inner Ear Physiology and Translational Science - read this article along with other careers information, tips and advice on BioSpace
Amirah Al Idrus
April 9, 2021
FierceBiotech
Project Onramp kicked off in 2019 to connect low-income students across Massachussetts to well-paid summer internships at local biotech companies. Since then, the internship program has weathered the COVID-19 pandemic, connected students and companies outside of Massachusetts through virtual internships and expanded into a new city: Philadelphia.
Amirah Al Idrus
March 23, 2021
FierceBiotech
Frequency Therapeutics is going back to the drawing board. After showing promise in phase 1, four dosing regimens of its hearing loss treatment did no better than placebo in a phase 2a study. The company will press ahead with a single-dose regimen and is waiting on final results from this study as well as readouts from two more phase 1b studies to plot its next steps.
BioSpace
December 1, 2020
BioSpace
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that it has named Peter P. Pfreundschuh as its new chief financial officer
Nguyen Thi Bich Ngoc
Invalid Date
DealStreetAsia
The round was joined by existing backers Polaris Founders Capital, Alexandria Venture Investments, CoBro Ventures, Korea Investment Partners and Emigrant Capital.
Is a
Company attributes
Crunchbase
Total funding amount (USD)
220,301,944
Latest funding round date
July 2020
Competitors
